Becton Dickinson and Co (BDX) : Mawer Investment Management Ltd. scooped up 200,572 additional shares in Becton Dickinson and Co during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 26, 2016. The investment management firm now holds a total of 1,527,358 shares of Becton Dickinson and Co which is valued at $246,301,751.Becton Dickinson and Co makes up approximately 2.81% of Mawer Investment Management Ltd.’s portfolio.
Becton Dickinson and Co closed down -0.36 points or -0.22% at $160.9 with 12,77,475 shares getting traded on Monday. Post opening the session at $160.67, the shares hit an intraday low of $157.6 and an intraday high of $162.24 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
Other Hedge Funds, Including , Boston Family Office boosted its stake in BDX in the latest quarter, The investment management firm added 270 additional shares and now holds a total of 7,604 shares of Becton Dickinson and Co which is valued at $1,226,221. Becton Dickinson and Co makes up approx 0.16% of Boston Family Office’s portfolio.Alpha Omega Wealth Management reduced its stake in BDX by selling 300 shares or 19.05% in the most recent quarter. The Hedge Fund company now holds 1,275 shares of BDX which is valued at $203,847. Becton Dickinson and Co makes up approx 0.17% of Alpha Omega Wealth Management’s portfolio.Highland Capital Management boosted its stake in BDX in the latest quarter, The investment management firm added 290 additional shares and now holds a total of 13,239 shares of Becton Dickinson and Co which is valued at $2,106,987. Becton Dickinson and Co makes up approx 0.18% of Highland Capital Management’s portfolio.Beese Fulmer Investment Management boosted its stake in BDX in the latest quarter, The investment management firm added 470 additional shares and now holds a total of 25,819 shares of Becton Dickinson and Co which is valued at $4,109,094. Becton Dickinson and Co makes up approx 1.18% of Beese Fulmer Investment Management’s portfolio.
On the company’s financial health, Becton Dickinson and Co reported $1.96 EPS for the quarter, beating the analyst consensus estimate by $ 0.12 according to the earnings call on Feb 3, 2016. Analyst had a consensus of $1.84. The company had revenue of $2986.00 million for the quarter, compared to analysts expectations of $3034.79 million. The company’s revenue was up 45.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.53 EPS.
Many Wall Street Analysts have commented on Becton Dickinson and Co. Company shares were Upgraded by Deutsche Bank on Feb 11, 2016 to ” Buy”, Firm has raised the Price Target to $ 163 from a previous price target of $155 .Shares were Reiterated by RBC Capital Mkts on Feb 4, 2016 to “Sector Perform” and Lowered the Price Target to $ 153 from a previous price target of $162 .
Becton Dickinson and Company is a global medical technology company engaged in the development manufacture and sale of a range of medical supplies devices laboratory equipment and diagnostic products used by healthcare institutions life science researchers clinical laboratories pharmaceutical industry and the general public. The Company operates through two segments: BD Medical and BD Life Sciences. The Company’s Life Sciences segment consists of the BD Diagnostics and BD Biosciences segments. The Company’s BD Medical segment focuses on providing solutions to reduce the spread of infection enhance diabetes treatment and advance drug delivery. The Company’s BD Diagnostics provides products for the safe collection and transport of diagnostics specimens as well as instruments and reagent systems. Its BD Biosciences provide diagnostic and research tools to life science researchers clinical researchers laboratory professionals and clinicians.